Biotech News
- Experimental drug treats gluten-caused intestinal damage in celiac patients
- Cipla recalls UTI drug in US
- Iambic, an AI drug discovery specialist, banks $150M in an IPO
- Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
14 October 2026
- STAT+: Trump administration delays new rule that could restrict imported medicines from Canada and overseas
- Sanofi's new R&D chief: Western pharma should rethink China's drug pipeline role
- The Best of BPI, Part 2
- The Best of BPI Early 2026
- New FDA framework tilts toward consistency over flexibility
- Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial
- Preterm Birth for Some Women Linked to Specific Autoantibodies
- Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
- J&J earnings set ‘negative tone’; Shkreli vs. the FTC
- Cell Therapy Manufacturing Takes Shape Across Asia-Pacific
- For Biocatalysis, Solvents are a Key Bioprocessing Parameter
- Turning Process Understanding Into Control of Lipid Nanoparticles
- Contracting Expansion: A Path to Better CAR T-Cell Therapy Production
- Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
- Verastem makes its stand as a RevMed competitor in pancreatic cancer
- Verastem cancer drug shows early promise in small study
- Minnesota Biomanufacturing Services quadruples capacity with new facility
- Oncolytics Biotech Reports GOBLET Study Results Timeline and PanCAN Grant Milestone
- GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum
- Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump
- STAT+: FDA adcomm members’ ties to industry under scrutiny
- Werbung
- GSK planning 1,200 job cuts in Belgium, says paper
- From bedside to breakthroughs: Reimagining the human experience in healthcare
- Rethinking Angina Treatment: Jed Litwiniuk and Uwe Tigör on Auxilius Pharma’s AUX001 | PharmaShots CXO Talks
- STAT+: Pharmalittle: We’re reading about Sanofi settling an EU antitrust probe, ‘pharma bro’ Shkreli, and more
- A new startup takes aim at a suspected culprit in autoimmune disease
- Clinical Trials Round-Up: July/August 2026
- Nxera Pharma Partners with Synmosa to Commercialize Quviviq Across Eight Asia-Pacific Markets
- STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine
- Vir makes solid tumor T cell engager deal with Gilead
- ISCR, CHAKRA sign MoU to strengthen clinical research capacity in Maharashtra
- MHRA lays out its thinking on AI and medicines regulation
- MHRA homes in on personalised healthcare and tech in new 2030 strategy
- Galderma to Acquire ZO Skin Health for $1.5B
- Arrowhead’s brain-targeting RNA drug lowers Alzheimer’s protein in early study
- Zealand inks up to $1.3B deal for AI-designed obesity treatments
- NIPER Raebareli, AstraZeneca India partner to expand clinical trial sites across India
- From botox to algorithms: How AI is redefining cosmetic medicine
- Trials to watch: First cancer vaccine success could trigger a domino effect
- Soufflé Therapeutics snags $135m to bring trio of drugs to the clinic
- GSK could cut more than 1,200 jobs in Belgium
- Zealand forges obesity alliance with AI specialist Generate
- Prelude Therapeutics and Lilly Collaborate to Evaluate PRT13722 Combinations in HR+/HER2- Breast Cancer
- IgniteData, RealTime join forces to automate clinical trial data transfers
- Charles River partners with Magellan Stem Cells on cell therapy
- Bespak and SNBL agree global access deal for FDA‑approved nasal device
- Werbung
- Biocon Inks settlement agreement with Roche for breast cancer drug
- BioNTech’s mRNA cancer vaccine misses Phase 2/3 endpoint
- NEMLUVIO data show sustained three‑year responses in atopic dermatitis
- Oncopeptides raises SEK 100 million after brain cancer breakthrough
- Sanofi escapes fine in EU mismarketing case
- New gene editing system offers promising CRISPR alternative
- Swedish electrode technology moves from lab to patients
- Swedish biotech raises SEK 100 million after brain cancer breakthrough
- Beyond technology exports into ‘NewCo and co-development’ – Successes and failures of new drug development cooperation from Chinese biotech companies
- BIX 2026 kicks off on October 28, spotlighting growth strategies for space biopharmaceuticals and companies
- Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Acquired Hypothalamic Obesity
- Preclinical Pulse: The research catching our eye in October 2026
- Biocon secures global settlement with Genentech for Pebrilzo launch
- FTC says Shkreli is flouting lifetime pharma ban
- Dosing completed in Calluna Pharma’s Phase II AURORA trial
- Zealand taps Generate’s AI discovery engine in $1.2B obesity deal
- Generate Biomedicines and Zealand Pharma Enter ~$1.2B AI-Driven Metabolic Disease Collaboration
- Pfizer partners with Enodia Therapeutics in $500m drug deal
- “The era of 30% weight loss” dawns as Eli Lilly presents its next-generation obesity treatment development strategy
- The secret to living 194 years? Ask Jonathan, the world’s oldest land animal
- AATec is pioneering a new approach to lung diseases
- Celltrion’s ‘Omlyclo’ competitiveness spotlighted in Japan as ‘first mover’ launch arrives
- Pin Therapeutics CEO Jo Hyun-sun: “Taking on global L/O with ‘PinMARS,’ a new protein-degrading agent platform”
- Shaperon's theoretical paper on 'limitations of steroid effects' accepted by international journal
- BioNTech Reports P-II/III Study Misses First Dual Primary Endpoint for BNT113 in HPV16-Positive Head and Neck Cancer
- Werbung
- This is how Denmark wants to renegotiate the MDR
- Godavari Biorefineries secures Mexican patent for antiviral research